Vepdegestrant is a small molecule commercialized by Arvinas, with a leading Phase III program in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer). According to Globaldata, it is involved in 17 clinical trials, of which 5 were completed, 9 are ongoing, and 3 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Vepdegestrant’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Vepdegestrant is expected to reach an annual total of $782 mn by 2034 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Vepdegestrant (ARV-471) is under development for the treatment of estrogen receptor positive and HER2 negative metastatic breast cancer. It is administered through oral route. The drug candidate is a heterobifunctional PROTAC (proteolysis-targeting chimera) and selective estrogen receptor degrader (SERD) acts by targeting estrogen receptor alpha and cereblon (CRBN).
Arvinas is a biopharmaceutical company that develops protein degradation therapeutics. The company develops novel therapeutics for the treatment of neuroscience, oncology, and other therapeutic areas. Its pipeline product includes ARV-471 for breast cancer, bavdegalutamide (ARV-110) for prostate cancer, and ARV-766 for the treatment of men with mCRPC. Arvinas’s protein degradation technology platform PROTAC Discovery Engine develops proteolysis-targeting chimera, or PROTAC-targeted protein degraders, and addresses a broad range of intracellular disease targets. The company intends to expand its transformative protein degradation technology and its product candidates into clinical development through collaborations with pharmaceutical companies. Arnivas is headquartered in New Haven, Connecticut, the US.
The company reported revenues of (US Dollars) US$131.4 million for the fiscal year ended December 2022 (FY2022), compared to a revenue of US$46.7 million in FY2021. The operating loss of the company was US$263.2 million in FY2022, compared to an operating loss of US$195.3 million in FY2021. The net loss of the company was US$282.5 million in FY2022, compared to a net loss of US$191 million in FY2021. The company reported revenues of US$34.6 million for the third quarter ended September 2023, a decrease of 36.5% over the previous quarter.
For a complete picture of Vepdegestrant’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.